We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+63.01%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$110M
Cap. Flow
+$14.9M
Cap. Flow %
4.02%
Top 10 Hldgs %
85.87%
Holding
30
New
2
Increased
12
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$5.8M
2
RPTX
Repare Therapeutics
RPTX
+$5.45M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.76M
4
KROS icon
Keros Therapeutics
KROS
+$3.36M
5
CGEM icon
Cullinan Oncology
CGEM
+$2.63M

Top Sells

Rank Stock Value
1
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$5.06M
2
TSVT
2seventy bio
TSVT
+$4.3M
3
NKTX icon
Nkarta
NKTX
+$3.44M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$3.21M
5
TRDA icon
Entrada Therapeutics
TRDA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Miscellaneous 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$94.5M 25.42%
1,601,785
-70,191
-4% -$3.21M
PLRX icon
2
Pliant Therapeutics
PLRX
$71.2M
$71.2M 19.15%
3,409,758
+302,951
+10% +$5.8M
CGEM icon
3
Cullinan Oncology
CGEM
$1.45B
$41.6M 11.18%
3,243,185
+195,576
+6% +$2.63M
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$37.2M 10.01%
3,069,847
+423,066
+16% +$5.45M
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$24.7M 6.65%
4,119,572
+337,373
+9% +$1.83M
KZR
6
DELISTED
Kezar Life Sciences
KZR
$15.2M 4.08%
176,279
-7,800
-4% -$758K
LRMR icon
7
Larimar Therapeutics
LRMR
$421M
$10.9M 2.94%
3,415,148
+1,900,000
+125% +$4.76M
AKUS
8
DELISTED
Akouos Inc
AKUS
$8.71M 2.34%
1,288,358
+452,238
+54% +$1.69M
TSVT
9
DELISTED
2seventy bio
TSVT
$7.71M 2.07%
530,223
-289,449
-35% -$4.3M
KROS icon
10
Keros Therapeutics
KROS
$223M
$7.53M 2.03%
200,229
+96,800
+94% +$3.36M
CMPX icon
11
Compass Therapeutics
CMPX
$454M
$6.45M 1.73%
2,829,712
– –
OMGA
12
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$5.72M 1.54%
1,055,882
– –
INZY
13
DELISTED
Inozyme Pharma
INZY
$5.35M 1.44%
1,996,277
-37,525
-2% -$136K
DTIL icon
14
Precision BioSciences
DTIL
$232M
$4.78M 1.28%
122,494
+22,369
+22% +$1.06M
IMA
15
ImageneBio Inc
IMA
$60.5M
$4.31M 1.16%
101,192
+10,281
+11% +$594K
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.05M 1.09%
323,945
-443,290
-58% -$5.06M
ORTX
17
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.99M 1.07%
798,740
+267,965
+50% +$1.49M
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.43M 0.92%
15,170
+8,837
+140% +$2.17M
FRLN
19
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$3.37M 0.91%
320,961
-3,194
-1% -$41.6K
RLYB icon
20
Rallybio
RLYB
$89M
$2.81M 0.76%
+24,287
New +$2.16M
ONCR
21
DELISTED
Oncorus, Inc.
ONCR
$2.01M 0.54%
2,367,436
– –
CRVS icon
22
Corvus Pharmaceuticals
CRVS
$1.24B
$1.95M 0.52%
2,384,402
+170,218
+8% +$162K
OVID icon
23
Ovid Therapeutics
OVID
$572M
$1.59M 0.43%
864,822
– –
NKTX icon
24
Nkarta
NKTX
$197M
$1.55M 0.42%
117,599
-240,414
-67% -$3.44M
LABD icon
25
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.2M
$1.2M 0.32%
+5,000
New +$1.16M
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, CHI Advisors held 30 positions worth $372M, up 42% from $262M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

CHI Advisors deployed $14.9M of net new capital in Q3 2022, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Rallybio: 24,287 shares worth $2.81M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was G1 Therapeutics, Inc. Common Stock, an estimated $5.06M trimmed.

  • CHI Advisors's largest Q3 2022 buy was Rallybio: 24,287 shares worth $2.81M.
  • CHI Advisors added most to Pliant Therapeutics in Q3 2022, an estimated $5.8M increase.
  • CHI Advisors's biggest Q3 2022 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $5.06M.
  • CHI Advisors fully exited Entrada Therapeutics in Q3 2022, selling an estimated $1.99M.
  • CHI Advisors's ten largest holdings make up 86% of its $372M portfolio in Q3 2022.
  • CHI Advisors opened 2 new positions and closed 5 in Q3 2022.
  • CHI Advisors's portfolio value rose 42% quarter-over-quarter to $372M.

Based on CHI Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.